In Sum
Dr. Utz left the audience with a great deal of food for thought in understanding the short and long-term implications of COVID-19 as it relates to autoantibody production. Much remains to learn on this topic.
Jason Liebowitz, MD, completed his fellowship in rheumatology at Johns Hopkins University, Baltimore, where he also earned his medical degree. He is an assistant professor of medicine in the Division of Rheumatology at Columbia University Vagelos College of Physicians and Surgeons.
References
- Zuo Y, Estes SK, Ali RA, et al. Prothrombotic autoantibodies in serum from patients hospitalized with COVID-19. Sci Transl Med. 2020 Nov;12(570):eabd3876.
- Magro C, Nuovo G, Mulvey JJ, et al. The skin as a critical window in unveiling the pathophysiologic principles of COVID-19. Clin Dermatol. 2021 Nov-Dec;39(6):934–965.
- Chang SE, Feng A, Meng W, et al. New-onset IgG autoantibodies in hospitalized patients with COVID-19. Nat Commun. 2021 Sep 14;12(1):5417.
- Hong GH, Ortega-Villa AM, Hunsberger S, et al. Natural history and evolution of anti-interferon-γ autoantibody-associated immunodeficiency syndrome in thailand and the united states. Clin Infect Dis. 2020 Jun 24;71(1):53–62.
- Bastard P, Rosen LB, Zhang Q, et al. Autoantibodies against type I IFNs in patients with life-threatening COVID-19. Science. 2020 Oct;370(6515):eabd4585.
- Muri J, Cecchinato V, Cavalli A, et al. Autoantibodies against chemokines post-SARS-CoV-2 infection correlate with disease course. Nat Immunol. 2023;24(4):604–611.
- Feng A, Yang EY, Moore AR, et al. Autoantibodies are highly prevalent in non-SARS-CoV-2 respiratory infections and critical illness. JCI Insight. 2023 Feb;8(3):e163150.
